Back to search

Article

Ecopipam (EBS-101) as a Novel Non-D2 Therapy for Tourette Syndrome: A Systematic Review and Meta-analysis of Prospective Clinical Studies

2026-07-30

Abstract excerpt

<h4>Background: </h4> Tourette syndrome (TS) is a neurodevelopmental disorder characterized by persistent motor and vocal tics. Current treatments mainly target dopamine D2 receptors but are often limited by adverse effects. Ecopipam, a selective dopamine D1 receptor antagonist, has emerged as a potential non-D2 therapeutic alternative. <h4>Methods:</h4> PubMed, Embase, Cochrane Library, Google Scholar, and Clinic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
de2e3637-1a3b-5877-9c11-34d9af9fbdc0
DOI
10.20944/preprints202607.2220.v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Ecopipam (EBS-101) as a Novel Non-D2 Therapy for Tourette Syndrome: A Systematic Review and Meta-analysis of Prospective Clinical StudiesDOI 10.20944/preprints202607.2220.v1
Select a neighboring publication to make it the new centre.